vs
Apellis Pharmaceuticals, Inc.（APLS）与Clearwater Analytics Holdings, Inc.（CWAN）财务数据对比。点击上方公司名可切换其他公司
Clearwater Analytics Holdings, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$217.5M vs $199.9M），Clearwater Analytics Holdings, Inc.净利率更高（-5.4% vs -29.5%，领先24.1%），Clearwater Analytics Holdings, Inc.同比增速更快（72.0% vs -5.9%），Clearwater Analytics Holdings, Inc.自由现金流更多（$52.3M vs $-14.3M），过去两年Clearwater Analytics Holdings, Inc.的营收复合增速更高（45.5% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Clearwater Analytics Holdings是美国SaaS金融科技企业，面向全球客户提供自动化投资会计、业绩测算、合规管理及风险报告服务。公司为公开上市企业，总部位于美国爱达荷州博伊西，在伦敦、爱丁堡、纽约、诺伊达多地设有分支机构。
APLS vs CWAN — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $217.5M |
| 净利润 | $-59.0M | $-11.8M |
| 毛利率 | — | 67.2% |
| 营业利润率 | -25.6% | -3.1% |
| 净利率 | -29.5% | -5.4% |
| 营收同比 | -5.9% | 72.0% |
| 净利润同比 | -62.2% | -102.8% |
| 每股收益（稀释后） | $-0.40 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $217.5M | ||
| Q3 25 | $458.6M | $205.1M | ||
| Q2 25 | $178.5M | $181.9M | ||
| Q1 25 | $166.8M | $126.9M | ||
| Q4 24 | $212.5M | $126.5M | ||
| Q3 24 | $196.8M | $115.8M | ||
| Q2 24 | $199.7M | $106.8M | ||
| Q1 24 | $172.3M | $102.7M |
| Q4 25 | $-59.0M | $-11.8M | ||
| Q3 25 | $215.7M | $-10.3M | ||
| Q2 25 | $-42.2M | $-23.2M | ||
| Q1 25 | $-92.2M | $6.5M | ||
| Q4 24 | $-36.4M | $419.3M | ||
| Q3 24 | $-57.4M | $3.6M | ||
| Q2 24 | $-37.7M | $-430.0K | ||
| Q1 24 | $-66.4M | $1.9M |
| Q4 25 | — | 67.2% | ||
| Q3 25 | — | 65.6% | ||
| Q2 25 | — | 65.1% | ||
| Q1 25 | — | 73.3% | ||
| Q4 24 | — | 73.5% | ||
| Q3 24 | — | 72.9% | ||
| Q2 24 | — | 72.0% | ||
| Q1 24 | — | 72.6% |
| Q4 25 | -25.6% | -3.1% | ||
| Q3 25 | 48.7% | 3.2% | ||
| Q2 25 | -18.6% | -8.0% | ||
| Q1 25 | -50.0% | 5.6% | ||
| Q4 24 | -12.3% | 1.0% | ||
| Q3 24 | -24.0% | 6.3% | ||
| Q2 24 | -14.7% | 3.6% | ||
| Q1 24 | -36.0% | -0.2% |
| Q4 25 | -29.5% | -5.4% | ||
| Q3 25 | 47.0% | -5.0% | ||
| Q2 25 | -23.6% | -12.8% | ||
| Q1 25 | -55.3% | 5.1% | ||
| Q4 24 | -17.1% | 331.5% | ||
| Q3 24 | -29.2% | 3.1% | ||
| Q2 24 | -18.9% | -0.4% | ||
| Q1 24 | -38.5% | 1.8% |
| Q4 25 | $-0.40 | $-0.04 | ||
| Q3 25 | $1.67 | $-0.04 | ||
| Q2 25 | $-0.33 | $-0.09 | ||
| Q1 25 | $-0.74 | $0.03 | ||
| Q4 24 | $-0.30 | $1.65 | ||
| Q3 24 | $-0.46 | $0.02 | ||
| Q2 24 | $-0.30 | $0.00 | ||
| Q1 24 | $-0.54 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $91.2M |
| 总债务越低越好 | — | $822.6M |
| 股东权益账面价值 | $370.1M | $2.0B |
| 总资产 | $1.1B | $3.0B |
| 负债/权益比越低杠杆越低 | — | 0.41× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $91.2M | ||
| Q3 25 | $479.2M | $64.1M | ||
| Q2 25 | $370.0M | $71.9M | ||
| Q1 25 | $358.4M | $282.9M | ||
| Q4 24 | $411.3M | $255.5M | ||
| Q3 24 | $396.9M | $305.8M | ||
| Q2 24 | $360.1M | $257.9M | ||
| Q1 24 | $325.9M | $267.6M |
| Q4 25 | — | $822.6M | ||
| Q3 25 | — | $838.9M | ||
| Q2 25 | — | $878.1M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $43.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $2.0B | ||
| Q3 25 | $401.2M | $2.0B | ||
| Q2 25 | $156.3M | $2.0B | ||
| Q1 25 | $164.2M | $1.1B | ||
| Q4 24 | $228.5M | $1.0B | ||
| Q3 24 | $237.1M | $403.2M | ||
| Q2 24 | $264.3M | $380.6M | ||
| Q1 24 | $266.7M | $406.2M |
| Q4 25 | $1.1B | $3.0B | ||
| Q3 25 | $1.1B | $3.0B | ||
| Q2 25 | $821.4M | $3.0B | ||
| Q1 25 | $807.3M | $1.3B | ||
| Q4 24 | $885.1M | $1.2B | ||
| Q3 24 | $901.9M | $623.5M | ||
| Q2 24 | $904.5M | $585.1M | ||
| Q1 24 | $831.9M | $547.8M |
| Q4 25 | — | 0.41× | ||
| Q3 25 | — | 0.42× | ||
| Q2 25 | — | 0.45× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $55.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $52.3M |
| 自由现金流率自由现金流/营收 | -7.1% | 24.0% |
| 资本支出强度资本支出/营收 | 0.1% | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $164.3M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $55.3M | ||
| Q3 25 | $108.5M | $49.0M | ||
| Q2 25 | $4.4M | $47.1M | ||
| Q1 25 | $-53.4M | $24.5M | ||
| Q4 24 | $19.4M | $-29.2M | ||
| Q3 24 | $34.1M | $49.6M | ||
| Q2 24 | $-8.3M | $43.9M | ||
| Q1 24 | $-133.0M | $10.0M |
| Q4 25 | $-14.3M | $52.3M | ||
| Q3 25 | $108.3M | $44.9M | ||
| Q2 25 | $4.4M | $44.1M | ||
| Q1 25 | $-53.4M | $23.0M | ||
| Q4 24 | $19.3M | $-30.0M | ||
| Q3 24 | — | $48.1M | ||
| Q2 24 | $-8.4M | $42.4M | ||
| Q1 24 | $-133.3M | $8.6M |
| Q4 25 | -7.1% | 24.0% | ||
| Q3 25 | 23.6% | 21.9% | ||
| Q2 25 | 2.5% | 24.2% | ||
| Q1 25 | -32.0% | 18.2% | ||
| Q4 24 | 9.1% | -23.7% | ||
| Q3 24 | — | 41.5% | ||
| Q2 24 | -4.2% | 39.7% | ||
| Q1 24 | -77.3% | 8.4% |
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 0.0% | 2.0% | ||
| Q2 25 | 0.0% | 1.6% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 0.6% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.2% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.76× | ||
| Q4 24 | — | -0.07× | ||
| Q3 24 | — | 13.66× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 5.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CWAN
暂无分部数据
